InvestSMART

Algorae Pharmaceuticals Limited (ASX:1AI)

ALERT: Price-sensitive ASX Announcement for 1AI
Current share price for 1AI : $0.013 0.003 (30%)+
Announcement
Release
28 Oct 2025 9:00AM
Price at Release
$0.010
Full Release
download
Summary
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical company, reported significant advancements in its operations for the quarter ending 30 September 2025. The company expanded its commercial activities in Australia and New Zealand through key partnerships with Sakar Healthcare Ltd and Cadila Pharmaceuticals Ltd to launch oncology and cardiovascular generics. The company also progressed its AI drug discovery platform, AlgoraeOS, and continued pre-clinical development of its therapeutic candidates. Financially, the company reported a net operating cash outflow of approximately $394,957, with cash reserves of $1.92 million as of the end of the quarter.
Key Points
  • Executed licensing agreement with Sakar Healthcare Ltd for oncology generics in Australia and New Zealand.
  • Signed a binding term sheet with Cadila Pharmaceuticals Ltd for launching generics in cardiovascular and metabolic markets.
  • Appointed Mr David Gulland as Chief Operating Officer.
  • Advanced AlgoraeOS Version 2.0 for AI drug discovery with multi-GPU architecture.
  • Conducted lab-in-the-loop validation with Peter MacCallum Cancer Centre.
  • Progressed pre-clinical development of AI-116 for Dementia and AI-168 for Cardiovascular.
  • Net operating cash outflow for the quarter was approximately $394,957.
  • Cash reserves at the end of the quarter were $1.92 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.